Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Approved
Development Phase
0
Upcoming Catalysts
1
Historical Events
1
Regulatory Approvals
1 competitor in KRAS G12C NSCLC
View Full LandscapeTarget Indication
KRAS G12C NSCLC
Mechanism of Action
KRAS G12C Inhibitor
Clinical Trial
NCT03600883Last updated: 12/3/2025
Latest Patent Expiry
Patents Listed
6
Exclusivity
Application
NDA 214665Lumykras
Lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy.